Each person should be considered equal first author for this work.
Biochemical, molecular characterization, and glycoproteomic analyses of α1-proteinase inhibitor products used for replacement therapy*
Version of Record online: 27 OCT 2006
Volume 46, Issue 11, pages 1959–1977, November 2006
How to Cite
Kolarich, D., Turecek, Peter L., Weber, A., Mitterer, A., Graninger, M., Matthiessen, P., Nicolaes, Gerry A.F., Altmann, F. and Schwarz, H. P. (2006), Biochemical, molecular characterization, and glycoproteomic analyses of α1-proteinase inhibitor products used for replacement therapy. Transfusion, 46: 1959–1977. doi: 10.1111/j.1537-2995.2006.01004.x
PLT, AW, AM, MG, PM, and HPS are employed by Baxter BioScience. DK, FA, and GAFN have received honoraria from Baxter BioScience. This work was supported by VIDI Grant 917.046.330 of the Dutch Organization for Scientific Research (NWO; to GAFN).
Presented in part at the “Aralast Structure Update” of the Medical and Scientific Advisory Committee of the Alpha 1 Foundation (September 27, 2005, Bethesda, MD) and at the Meeting of the Blood Product Advisory Committee of the FDA (November 4, 2005, Gaithersburg, MD).
- Issue online: 27 OCT 2006
- Version of Record online: 27 OCT 2006
- Received for publication February 13, 2006; revision received April 19, 2006, and accepted April 26, 2006.
Vol. 47, Issue 8, 1558, Version of Record online: 25 JUL 2007
The following supplementary material is available for this article "Biochemical, molecular characterization, and glycoproteomic analyses of a1-proteinase inhibitor products used for replacement therapy" online: Table 4.
|table+4+for+trf+1004+(supp+mat).pdf||34K||Supporting info item|
|trf01004_supplementary_table.doc||29K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.